European Association for the Study of Diabetes (EASD) 2009
C-peptide Correction Method to Determine Exogenous Insulin Levels in Pharmacokinetic Studies Using Technosphere® Insulin
C-peptide Abstract
C-peptide Poster
Inhaled GLP-1 and Exenatide: Different Effects on Pancreatic and Gastric Activity Following a Single Dose in Type 2 Diabetes Mellitus
Inhaled GLP-1 Effects on Pancreatic and Gastric Activity Abstract
Inhaled GLP-1 Effects on Pancreatic and Gastric Activity Poster
Response to Inhaled GLP-1 is Dependent on Baseline Glucose
Response to Inhaled GLP-1 Abstract
Response to Inhaled GLP-1 Poster
Basal/Bolus With Prandial Inhaled Technosphere® Insulin (TI) Plus Insulin Glargine QD vs Biaspart 70/30 Insulin BID in T2 DM Inadequately Controlled on Insulin With/Without Oral Agents
Basal/Bolus With Prandial Inhaled Technosphere® Insulin (TI) Abstract
Basal/Bolus With Prandial Inhaled Technosphere® Insulin (TI) Poster
Reduced Incidence and Frequency of Hypoglycemia in an Integrated Analysis of Pooled Data from Clinical Trials of Subjects with Type 2 Diabetes Using Prandial Inhaled Technosphere® Insulin
Clinical Trials of Subjects with Type 2 Diabetes Abstract
Clinical Trials of Subjects with Type 2 Diabetes Poster
Pulmonary Function Tests Remain Similar in Patients Who Received Technosphere® Insulin and in Patients Currently Receiving Standard Antidiabetic Therapy
Patients Currently Receiving Standard Antidiabetic Therapy Abstract
Patients Currently Receiving Standard Antidiabetic Therapy Poster
Pulmonary Functions (Over 2 Years) in Diabetic Subjects Treated with Technosphere® Insulin or Usual Antidiabetic Treatment
Diabetic Subjects Treated with Technosphere® Insulin Abstract
Diabetic Subjects Treated with Technosphere® Insulin Poster
Pulmonary Safety of Inhaled Technosphere® Insulin Therapy in Adults with Diabetes Using High-Resolution Computerized Tomography of the Chest
Pulmonary Safety of Inhaled Technosphere® Insulin Abstract
Pulmonary Safety of Inhaled Technosphere® Insulin Poster
Technosphere® Insulin Suppresses Endogenous Glucose Production Earlier Than a Rapid-Acting Analog (Lispro) and an Inhaled Insulin (Exubera)
Technosphere® Insulin Suppresses Endogenous Glucose Abstract
Technosphere® Insulin Suppresses Endogenous Glucose Poster
Pharmacokinetics of Technosphere® Insulin Unchanged in Patients with Chronic Obstructive Pulmonary Disease
Pharmacokinetics of Technosphere® Insulin Abstract
Pharmacokinetics of Technosphere® Insulin Poster
Lung Deposition and Absorption of Insulin from Technosphere® Insulin
Lung Deposition and Absorption of Insulin Abstract
Lung Deposition and Absorption of Insulin Poster
Comparative Efficacy and Safety of Technosphere® Insulin and a Rapid-Acting Analog Both Given With Glargine in Subjects with T1 DM in a 52-Week Study
Comparative Efficacy and Safety of Technosphere® Insulin Abstract
Comparative Efficacy and Safety of Technosphere® Insulin Poster
Reduced Incidence and Frequency of Hypoglycemia in an Integrated Analysis of Pooled Data from Clinical Trials of Subjects with Type 1 Diabetes Using Prandial Inhaled Technosphere® Insulin
Reduced Incidence and Frequency of Hypoglycemia Abstract
Reduced Incidence and Frequency of Hypoglycemia Poster
Patient Reported Outcomes in Adults with Type 2 Diabetes Using Mealtime Insulin Monomer Human (rDNA origin) Inhalation Powder (Technosphere® Insulin Inhalation Powder) or Metformin + Secretagogue or Both
Patient Reported Outcomes in Adults with Type 2 Diabetes Abstract
Patient Reported Outcomes in Adults with Type 2 Diabetes Poster
Long-term Sustained Safety and Efficacy of Continued Use of Technosphere® Insulin in Subjects with Type 2 Diabetes (Oral Presentation)
Long-term Sustained Safety and Efficacy Abstract
|
